{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:25:50Z","timestamp":1761895550799,"version":"3.44.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.metabol.2012.08.011","type":"journal-article","created":{"date-parts":[[2012,9,21]],"date-time":"2012-09-21T13:00:37Z","timestamp":1348232437000},"page":"386-391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effect of low dose mineralocorticoid receptor antagonist eplerenone on glucose and lipid metabolism in healthy adult males"],"prefix":"10.1016","volume":"62","author":[{"given":"Alexander W.","family":"Krug","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lissy","family":"Stelzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajaykumar D.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew H.","family":"Lichtman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon H.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail K.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2012.08.011_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10741-005-2343-3","article-title":"Aldosterone biosynthesis, regulation, and classical mechanism of action","volume":"10","author":"Williams","year":"2005","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.metabol.2012.08.011_bb0010","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1210\/en.2010-0465","article-title":"Minireview: aldosterone and mineralocorticoid receptors: past, present, and future","volume":"151","author":"Funder","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2012.08.011_bb0015","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.pcad.2009.12.003","article-title":"Aldosterone and mineralocorticoid receptors in the cardiovascular system","volume":"52","author":"Funder","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.metabol.2012.08.011_bb0020","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1161\/HYPERTENSIONAHA.107.109439","article-title":"Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor?","volume":"51","author":"Krug","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.metabol.2012.08.011_bb0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1161\/01.HYP.25.1.30","article-title":"Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans","volume":"25","author":"Goodfriend","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.metabol.2012.08.011_bb0030","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1210\/jc.2006-0736","article-title":"Insulin sensitivity in patients with primary aldosteronism: a follow-up study","volume":"91","author":"Catena","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2012.08.011_bb0035","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1001\/archinte.164.19.2090","article-title":"Postprandial glucose regulation and diabetic complications","volume":"164","author":"Ceriello","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.metabol.2012.08.011_bb0040","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2010-3011","article-title":"Cardiovascular disease in diabetes: where does glucose fit in?","volume":"96","author":"Reusch","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2012.08.011_bb0045","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00041433-199510000-00008","article-title":"Postprandial state and atherosclerosis","volume":"6","author":"Ebenbichler","year":"1995","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.metabol.2012.08.011_bb0050","first-page":"129","article-title":"Fatty acids and postprandial inflammation","volume":"12","author":"Margioris","year":"2009","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.metabol.2012.08.011_bb0055","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2012.08.011_bb0060","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1161\/01.CIR.0000140677.20606.0E","article-title":"Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults","volume":"110","author":"Malik","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2012.08.011_bb0065","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1161\/01.CIR.0000165070.46111.9F","article-title":"Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients","volume":"111","author":"Ceriello","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2012.08.011_bb0070","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1056\/NEJM196511182732106","article-title":"Hypertension, the potassium ion and impaired carbohydrate tolerance","volume":"273","author":"Conn","year":"1965","journal-title":"N.Engl.J.Med"},{"key":"10.1016\/j.metabol.2012.08.011_bb0075","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2002-030024","article-title":"Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders","volume":"89","author":"Skrha","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2012.08.011_bb0080","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/HJH.0b013e3280108e6f","article-title":"Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study","volume":"25","author":"Giacchetti","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.metabol.2012.08.011_bb0085","first-page":"21","article-title":"Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment","volume":"108","author":"Sindelka","year":"2000","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.metabol.2012.08.011_bb0090","doi-asserted-by":"crossref","first-page":"503","DOI":"10.33549\/physiolres.930298","article-title":"Does the treatment of primary hyperaldosteronism influence glucose tolerance?","volume":"52","author":"Strauch","year":"2003","journal-title":"Physiol Res"},{"key":"10.1016\/j.metabol.2012.08.011_bb0095","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1161\/HYPERTENSIONAHA.107.093955","article-title":"Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells","volume":"50","author":"Hitomi","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.metabol.2012.08.011_bb0100","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/MED.0b013e3283533955","article-title":"Role of mineralocorticoid receptor in insulin resistance","volume":"19","author":"Garg","year":"2012","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.metabol.2012.08.011_bb0105","first-page":"217","article-title":"Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure","volume":"17","author":"Craft","year":"2004","journal-title":"Proc.(Bayl.Univ Med.Cent.)"},{"key":"10.1016\/j.metabol.2012.08.011_bb0110","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0952-3278(99)80020-9","article-title":"Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans","volume":"60","author":"Goodfriend","year":"1999","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.metabol.2012.08.011_bb0115","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/01.HYP.0000231338.41548.fc","article-title":"Plasma aldosterone is independently associated with the metabolic syndrome","volume":"48","author":"Bochud","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.metabol.2012.08.011_bb0120","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1210\/jc.2005-1733","article-title":"Prevalence and characteristics of the metabolic syndrome in primary aldosteronism","volume":"91","author":"Fallo","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2012.08.011_bb0125","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.amjhyper.2004.12.005","article-title":"Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study","volume":"18","author":"Kathiresan","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.metabol.2012.08.011_bb0130","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1210\/en.2009-0869","article-title":"Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet","volume":"151","author":"Wada","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2012.08.011_bb0135","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1161\/CIRCULATIONAHA.107.748640","article-title":"Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines","volume":"117","author":"Guo","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2012.08.011_bb0140","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/cvr\/cvp191","article-title":"Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice","volume":"84","author":"Hirata","year":"2009","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.metabol.2012.08.011_bb0145","doi-asserted-by":"crossref","DOI":"10.1292\/jvms.12-0007","article-title":"Spironolactone, but not eplerenone, impairs glucose tolerance in a rat model of metabolic syndrome","author":"Homma","year":"2012","journal-title":"J Vet Med Sci"},{"key":"10.1016\/j.metabol.2012.08.011_bb0150","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2337\/dc08-1709","article-title":"Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program","volume":"32","author":"Preiss","year":"2009","journal-title":"Diabetes Care"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049512003150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049512003150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T03:59:52Z","timestamp":1758427192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049512003150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0026049512003150"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2012.08.011","relation":{},"ISSN":["0026-0495"],"issn-type":[{"type":"print","value":"0026-0495"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of low dose mineralocorticoid receptor antagonist eplerenone on glucose and lipid metabolism in healthy adult males","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2012.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}